Floatz logo

GIMERACIL

Adjuvant Chemotherapy

Peking University Cancer Hospital & InstituteSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Adjuvant Chemotherapy cohort.

Asset / SponsorPhaseRating
Peg-Rhg-Csf
Shandong University
Phase 4BB
Eloxatin
Fudan University
Phase 3BB
Capecitabine
Fudan University
Phase 3BB
Nivolumab
Fundación GECP
Phase 3B
OTERACIL
Peking University Cancer Hospital & Institute
Phase 3B

View all 21 →

Same molecule, other indications

GIMERACIL is also rated in:

Colorectal Cancer Stage IIIDormant
B
Indicative ·
60 / 100
View asset →
pancreatic neoplasmDormant
CC
Indicative ·
46 / 100
View asset →
Breast CancerDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →